Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02881853 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, and Bioavailability of Subcutaneously Administered XmAb®7195
A Phase 1 study, sponsored by Xencor.
- Completed
- Registry status
- Phase 1
- Development phase
- 57
- Enrollment target
NCT02881853 is a Phase 1 study that has completed, run by Xencor. The registered enrollment target is 57 participants.
The verdict
NCT02881853, a Phase 1 study, has completed, sponsored by Xencor.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 57 participants
- Enrollment target
Study Summary
This is a Phase 1b, combined multiple dose subcutaneous (SC) bioavailability (BA) and multiple ascending dose (MAD) study evaluating safety, tolerability and BA of SC XmAb7195 in healthy subjects and in subjects with atopic disease.
Interventions
- DRUG Placebo
- DRUG XmAb7195
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2016-08-17 |
| Est. Completion | 2017-02-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02881853
The ClinicalTrials.gov registry entry for NCT02881853 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Xencor, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02881853 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02881853 about?
NCT02881853 is a clinical study titled "Safety, Tolerability, and Bioavailability of Subcutaneously Administered XmAb®7195". This is a Phase 1b, combined multiple dose subcutaneous (SC) bioavailability (BA) and multiple ascending dose (MAD) study evaluating safety, tolerability and BA of SC XmAb7195 in healthy subjects and in subjects with atopic disease.
What is the current status of trial NCT02881853?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 57 participants. The study started on 2016-08-17. Estimated completion is 2017-02-24.
What interventions are being tested in trial NCT02881853?
The interventions under investigation include: Placebo (DRUG), XmAb7195 (DRUG).
Who is sponsoring clinical trial NCT02881853?
This trial is sponsored by Xencor, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.